THE PARIS SYSTEM FOR URINE CYTOLOGY NUCLEAR TO CYTOPLASMIC RATIO
ASC Poster Presentation
How does artificial intelligence redefine N:C ratio thresholds for diagnosing high-grade urothelial carcinoma?
Resources and News
Educational resources and news from AIxMed to keep you informed
and up-to-date on our AI empowered digital cytology solutions.
and up-to-date on our AI empowered digital cytology solutions.
.png)
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AIxURO URINE CYTOLOGY CLINICAL STUDIES
March 2026
USCAP 2026 Oral Presentation
AI-Powered Urine Cytology: Redefining Diagnostic Precision and Workflow at PathNet
USCAP 2026 Oral Presentation
AI-Powered Urine Cytology: Redefining Diagnostic Precision and Workflow at PathNet
STUDY DESIGN:
RESULTS:
The implementation of AIxURO™ at PathNet has delivered a comprehensive set of clinical and operational advantages by bridging the gap between digital pathology and automated analytical software. By integrating this tool into the daily workflow, the laboratory realized several key benefits:
Strategic Clinical Uses
- Cyto-Histo Correlation: The platform serves as a powerful additional tool for correlating cytology findings with surgical pathology results.
- Quality Control Review: AIxURO™ provides a robust QC layer, acting as atireless "second set of eyes" to confirm results and reduce human fatigue.
- Educational Advancement: The digitized data and statistical analysis offer a modernized platform for the training and education of cytologists, residents and fellows.
Operational and Patient Benefits
- Cost-Effectiveness: Patients benefit from a reduction in unnecessary and expensive ancillary testing, such as UroVysion FISH, as the AI's precision assists in increased diagnostic confidence.
- Workflow Efficiency: The laboratory observed an increase in both cytologist and pathologist efficiency, particularly through the use of superior digital imaging.
- Ergonomics and Reliability: Beyond technical accuracy, the transition to digital analysis improved the physical ergonomics for cytologists and ensured the consistent confirmation of negative cases.
CONCLUSIONS:
PathNet’s success proves that the future of pathology lies in the synergy between human expertise and machine learning. By embedding AI within the existing digital workflow, PathNet has empowered its staff to work more efficiently and comfortably while setting a new global standard for patient care.
AIxURO URINE CYTOLOGY CLINICAL STUDIES
March 2026
USCAP 2026 Oral Presentation
Objective Precision in the Caribbean: CorePlus and the Future of AI-Driven Pathology
USCAP 2026 Oral Presentation
Objective Precision in the Caribbean: CorePlus and the Future of AI-Driven Pathology
STUDY DESIGN:
RESULTS:
The laboratory conducted a comprehensive validation study involving 117 cases across a wide range of diagnostic categories (benign, AUC, HGUC). The results showed:
- High Concordance: A 93.7% concordance rate between manual microscopy and the AI-driven
- Statistical Robustness: High sensitivity (90.4%) and specificity (94.1%),demonstrating the AI's ability to accurately identify HGUC cases while maintaining low false-positive rates.evaluation.
CONCLUSIONS:
CorePlus has demonstrated that private laboratories can lead the way in adopting advanced AI technology. By prioritizing patient care and investing in digital tools, the lab has achieved unprecedented efficiency and diagnostic precision.
AIxURO URINE CYTOLOGY CLINICAL STUDIES
March 2026
USCAP 2026 Oral Presentation
Digital Cytopathology in the Heart of Europe: A Bioptická Laboratoř Experience
USCAP 2026 Oral Presentation
Digital Cytopathology in the Heart of Europe: A Bioptická Laboratoř Experience
STUDY DESIGN:
RESULTS:
The implementation of the AI-driven workflow resulted in significant improvements:
- Increased Speed: Pathologists reported a 30% to 50% increase in workflow speed, with the diagnosis of benign cases often reduced to mere seconds.
- Enhanced Sensitivity: The AI was slightly biased toward sensitivity, ensuring that atypical cells were prioritized for review.
- Objective Data: The system provides quantitative metrics for atypical and suspicious cells, removing subjectivity from the diagnostic process.
- Improved Efficiency: The reduction in screening time allowed the lab to free up capacity for growth without compromising accuracy.
CONCLUSIONS:
Clinical use of AIxURO resulted in a 30–50% faster overall read time, improved sensitivity with moreobjective data for atypical cases, and a noticeably better user experience. The system is easy to use,avoids unnecessary features, integrates well with glass slides, and supports increased efficiency andgrowth in routine clinical practice.
November 2024
How does artificial intelligence redefine N:C ratio thresholds for diagnosing high-grade urothelial carcinoma?
ASC 2024 Poster Presentation Hang JF, Yang WL, Yeh CH et al. TVGHTE, Natl Tung University, Show Chwan Mem Hospital, Tungs MetroHarbor Hospital N:C ratio pilot study_2024
STUDY DESIGN:
- 109 urine cytology cytospin cases with surgically-confirmed HGUC, HGUC-CIS, “positive” or CIS within a 6 month pre-or post-urine collection window
- Digitally analyzed by AIxURO AI-deep learning software for N/C ratio and nuclear area for the cytologic specimen diagnoses of AUC, SHGUC, and HGUC
- Comparison of the cytologic and surgical diagnoses by mean cell numbers per slide, mean N/C ratio, and mean nuclear area (µm2)
RESULTS:
- Cell Quantification: AIxURO categorized fewer suspicious cells (mean 160.0) compared to atypical cells (mean 929.6)
- N/C Ratio and Nuclear Area: Suspicious cells had higher mean N/C ratio (0.66 vs 0.58) and higher mean nuclear area (107.2 vs 66,9 µm2) than atypical cells
- Mean N/C for suspicious cells across all biopsies = 0.65 to 0.68
- Larger nuclear areas were also noted in SHGUC (13.9% difference) and HGUC (24.4% difference)
- Carcinoma in situ (CIS) had the largest mean nuclear area for both suspicious (117.3 µm2) and atypical (101.1 µm2) cells
CONCLUSIONS:
A lower mean N/C ratio for suspicious cells as an indicator of biopsy-proven HGUC using TPS should be considered, especially for AI-assisted urine cytology software programs. AIxURO categorized suspicious cells have a higher nuclear area than categorized atypical cells. Very large nuclear areas may be an indicator of CIS.
November 2024
WHOLE SLIDE IMAGE SCANNER STUDIES
Pathology Visions Poster Presentation
Do different digital imagers used with the AIxURO system impact performance in urine cytology?
Do different digital imagers used with the AIxURO system impact performance in urine cytology?
DPA 2024 Poster Presentation / Abstract Yang WL, Yang WC, Huang SM, et al. Show Chwan Hospital and AIxMED (pilot studies 2 & 3)
STUDY DESIGN:
- 183 urine cytology slides (140 CytoRich, 43 SurePath), with expert panel consensus diagnoses as NHGUC (83), AUC (45), SHGUC (27), and HGUC (28)
- Slides scanned by Leica AT2 and Hamamatsu S360 digital scanners with images inferred by the AI algorithm (AIxURO), using The Paris System (TPS) 2.0 criteria
- AIxURO separated abnormal cells into “suspicious” and “atypical” categories for investigator review
- 3-Arm Study:
- 6 reviewers (1 cytopathologist and 5 cytologists) interpreted the slides using conventional microscopy only (Arm 1), Leica whole slide image (WSI) with AIxURO AI-assistance (Arm 2), and Hamamatsu WSI with AIxURO AI-assistance (Arm 3) with a 2-week wash-out period between reviews
RESULTS:
3294 total reviews (microscopy + WSI + AIxURO); binary distribution as positive (AUC, SHGUC, or HGUC) or negative (NHGUC)
- Sensitivity and Specificity of AIxURO with Leica: 85.0% and 90.0%
- Sensitivity and Specificity of AIxURO with Hamamatsu: 82.9% and 89.6%
- Sensitivity and Specificity of microscopy only: 83.7% and 89.4%
- Total Time for review of AIxURO with Leica: 37.4 seconds
- Total Time for Review of AIxURO with Hamamatsu: 53.1 seconds
- Total Time for Review of microscopy only: 82.0 seconds
- Reviewers (3) experienced with the AIxURO system had higher sensitivity (91.3% vs 78.7%) but lower specificity (87.7% vs 92.3%) and spent less time (30.6 sec vs 44.4 sec) than the 3 without experience
CONCLUSIONS:
Use of AI-assisted software (AIxURO) to classify abnormal urothelial cells into atypical or suspicious categories improved the overall sensitivity and specificity for a binary interpretation over conventional microscopy. Additionally, AI-assistance significantly reduced reporting time by 52.4% (AIxURO + Leica AT2) and 35.2% (AIxURO + Hamamatsu) compared to microscopy. Experienced users of AIxURO showed better overall performance, suggesting that training and experience with AI-assistance will improve performance.
November 2024
AIxURO URINE CYTOLOGY CLINICAL STUDIES
Pathology Visions Poster Presentation
Transforming bladder cancer diagnosis via AI-aided digital cytology integration in clinical workflow
Transforming bladder cancer diagnosis via AI-aided digital cytology integration in clinical workflow
DPA 2024 Poster Presentation / Abstract Sigfred Lajara, MD; Samer Khader, MD; Rajiv Dhir, MD; Daniel Geisler, MD; Jacqueline Cuda, SCT; Caroline Horne, SCT UPMC pilot study
STUDY DESIGN:
- 200 ThinPrep urine cytology slides (100 NHGUC, 35 AUC, 32 SHGUC, 33 HGUC) with diagnostic confirmation by 3 expert pathologists were digitized to WSIs using Mikroscan SLxCyto and analyzed by an AI-assisted program, AIxURO
- 1 cytopathologist (CP) and 2 cytologists (CT) reviewed urine slides or AI-assisted images with a 2-week washout period between reviews
- Arm 1: Microscopic review
- Arm 2: AI-assisted software (AIxURO) review
- Performance Metrics: Comparison of 2 diagnostic positive thresholds: AUC+ (AUC, SHGUC, and HGUC) and SHGUC+ (SHGUC and HGUC) and total time for interpretation
RESULTS:
- AI-assisted AIxURO showed higher sensitivity (85% vs 79.3%) but lower specificity (92% vs 98%) than microscopy overall, using AUC+ as the positive threshold
- AIxURO showed lower sensitivity (74.9% vs 76.9%) and specificity (96% vs 97.5%) than microscopy using SHGUC+ as the positive threshold.
- Review Time: AIxURO markedly reduced review time (37.4 s) compared to microscopy (102.6 s) overall. CTs spent almost double the time for microscopy (121.6 s) compared to the CP (64.6 s).
CONCLUSIONS:
AIxURO showed a 5.7% increase in sensitivity and 8.6% decrease in specificity compared to microscopy, suggesting that while AIxURO helps to ID more positive cases, it results in higher false positives. At SHGUC+ threshold, AIxURO showed a 2% decrease in sensitivity and 1.5% decrease in specificity, suggesting that reviewers diagnose more cases as AUC than with microscopy. AIxURO saves reviewers 63.5% of evaluation time compared to microscopy, at more consistent evaluation times. CTs spend substantially less evaluation time than CP using AIxURO.
November 2024
AIxURO URINE CYTOLOGY CLINICAL STUDIES
Pathology Visions Poster Presentation
Revolutionizing bladder cancer diagnosis: Insights on urine cytology from a digital pathology lab
Revolutionizing bladder cancer diagnosis: Insights on urine cytology from a digital pathology lab
DPA 2024 Poster Presentation / Abstract CorePlus pilot study
STUDY DESIGN:
- 100 CytoRich urine cytology slides with 3 expert consensus interpretations as ground truth (68 NHGUC, 11 AUC, 7 SHGUC, 14 HGUC) scanned with Mikroscan SLxCyto to form WSI, which was in turn analyzed with deep learning AI model (AIxURO) trained on The Paris System criteria for urine cytology reporting
- 1 cytopathologist and 2 cytologists microscopically reviewed the glass slide and digitally reviewed the WSI and AIxURO images, with a 2-week washout between each, resulting in 300 diagnostic pairs per observer
- Diagnostic pairs were compared with the ground truth; total time to report recorded; and sensitivity, specificity recorded per observer
RESULTS:
- Sensitivity: For a binary diagnosis (negative = NHGUC; positive = AUC, SHGUC, HGUC), AIxURO showed higher sensitivity overall (88.5% vs 86.5%) than microscopy for all observers
- CT1: 84.4% vs. 87.5%
- CT2: 90.6% vs. 90.6%
- CP: 90.6% vs. 81.3%
- Specificity was lower overall for AIxURO (93.6% vs. 97.6%) compared to microscopy
- CT1: 91.2% vs. 94.1%
- CT2: 98.5% vs. 98.5%
- CP: 91.2% vs. 100.0%
- Reporting time: AIxURO substantially reduced mean reporting time for all observers compared to microscopy (13.6 seconds vs 83.3 seconds); this was especially pronounced for negative cases (7.7 seconds vs 72.3 seconds
CONCLUSIONS:
AI-assisted software (AIxURO) substantially reduces overall interpretation and reporting time by 83.3% compared to conventional microscopy. AIxURO also improves sensitivity for a binary (positive vs negative) diagnosis but is less specific than microscopic interpretation.
November 2024
AI SOFTWARE DEVELOPMENT
Academic Article: In Vivo
An artificial intelligence-assisted diagnostic system improves upper urine tract cytology diagnosis
An artificial intelligence-assisted diagnostic system improves upper urine tract cytology diagnosis
In Vivo 2024; 38(x): published ahead of print; doi:10.21873/invivo.11xxx Chang KY, Yang CS, Lai HY et al. VGHTC; Nat’l Chung Hsing University; Chung Shan Medical University
STUDY DESIGN:
- Retrospective cohort study
- 185 upper tract urine cytology slides (168 NHGUC, 14 AUC, 2 SHGUC, 1 HGUC) with one expert cytopathologist (CP) and one experienced cytologist (CT) confirmation of interpretation; discrepancies in diagnosis were resolved by multiheaded microscopy review by expert panel
- Digitized using Aperio AT2 scanner (Leica Biosystems) at 40X and single Z-plane
- Deep-learning training
RESULTS:
- Cases ranked by AI-driven software into low risk (N/C 0.5 to 0.7) or high risk (N/C > 0.7)
- 37 discrepant results after AI analysis (AIxURO)
- Discrepancies (AIxURO vs conventional):
- Cytopathologist:
- Overcalled 1 NHGUC as SHGUC
- Undercalled 2 AUC as NHGUC
- Cytologist:
- Overcalled 3 NHGUC as AUC and 2 AUC as SHGUC
- Undercalled 9 AUC as NHGUC, and 1 SHGUC
- o NHGUC (20 of 168; 11.9% discrepancy rate)
- Cytopathologist:
CONCLUSIONS:
Diagnostic accuracy is achieved in at least 85.7% for atypical and suspicious cells in the AUC and above categories, with AUC showing the least concordance (21.4% accuracy). The use of AI-assistance markedly reduced the miscall rate for the CP but not the CT compared to reported misdiagnosis rates as high as 27.6% (57 million cases in China).
July 2024
AIxURO URINE CYTOLOGY CLINICAL STUDIES
Academic Article: Cancer Cytopathology
Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis
Evaluating artificial intelligence–enhanced digital urine cytology for bladder cancer diagnosis
STUDY DESIGN:
- 116 urine (76 cytospin; 40 CytoRich) cytology slides with 3-armed microscopy, corresponding WSI and AI-digital (AIxURO) review by 1 experienced cytopathologist and 2 cytologists
- Performance metrics calculated for each arm included binary (negative vs positive) diagnosis, inter-and intra-observer agreement, and screening time
RESULTS:
- Atypical Urothelial Cells (AUC): AIxURO improved diagnostic sensitivity (from 25-30.6% to 63.9%), PPV (from 21.6-24.3% to 31.1%), and NPV (91.3-19.6%) to 95.3%)
- Suspicious for High-Grade Urothelial Carcinoma (SHGUC): AIxURO improved sensitivity (from 15.2-27.3% to 33.3%), PPV (from 31.3-47.4% to 61.1%), and NPV (from 91.6%-92.7% to 93.3%).
- Binary Diagnosis (Negative vs Positive [AUC, SHGUC, or HGUC]): AIxURO improved sensitivity (from 77.8-82.2% to 90.0%) and NPV (from 91.7-93.4% to 95.8%)
- Interobserver agreement: Moderate concurrence across all methods of evaluation (ĸ = 0.57-0.61); cytopathologist showed the highest intraobserver agreement (ĸ = 0.75-0.88)
- Screening time: AIxURO significantly reduced screening time compared to conventional microscopy for all observers (by 52.3% to 83.2%); AUC case
CONCLUSIONS:
The most significant finding is the marked reduction in screening time for AI-enhancement (AIxURO) compared with conventional microscopy (up to 83% less time required). Implementation of AI enhancement (AIxURO) for urine cytology interpretation improves diagnostic sensitivity, PPV and NPV for AUC and SHGUC, but not HGUC.
AIxURO improves the sensitivity and NPV of a binary interpretation of negative or positive. The interobserver agreement across all methods of review (microscopy, WSI and AIxURO) is moderate (ĸ = 0.57-0.61) with the cytopathologist showing the highest intra-observer agreement.
June 2024
AIxURO URINE CYTOLOGY CLINICAL STUDIES
ECDP Poster Presentation
A comparative study of artificial intelligence integration in bladder cancer screening: Enhancing accuracy and efficiency
A comparative study of artificial intelligence integration in bladder cancer screening: Enhancing accuracy and efficiency
ECDP 2024 Poster Presentation / Abstract Show Chwan Hospital, clinical pilot study 2
STUDY DESIGN:
- 200 urine cytology slides (100 positive, 100 negative) were scanned to create whole slide images (WSI) that were analyzed by an artificial intelligence (AI)-assisted software program (AIxURO) to detect and quantify characteristics of abnormal urothelial cells
- Three study arms, each performed by 3 reviewers (1 cytopathologist, 2 cytologists) rendering the Paris System (TPS) 2.0 interpretation (2-week washout period between each arm):
- ARM 1- Glass slide microscopic interpretation
- ARM 2- Whole slide image interpretation
- ARM 3- WSI with AI-assisted interpretation (AIxURO)
- Performance Metrics: Total screening/reporting time, sensitivity and specificity compared to the ground truth diagnosis
RESULTS:
- Average screening and reporting time was significantly reduced by 25.8%-58.7% (p < 0.05)
- Microscopy only and AI-assisted (AIxURO) outperformed WSI-only review in both sensitivity and specificity
- AIxURO was slightly less sensitive than microscopy (66.0 - 87.0% vs. 86.0 -89.0%) but more specific (89.0 – 95.0% vs. 81.0 – 88.0%).
- Use of AIxURO reclassified some ground-truth diagnoses from HGUC or SHGUC to AUC or NHGUC.
CONCLUSIONS:
The use of an AI-assisted software platform (AIxURO) for detection of bladder carcinoma improves overall specificity in comparison with microscopic glass slide or whole slide imaging review, while significantly reducing screening and reporting time.
June 2024
SOFTWARE OPTIMIZATION & VALIDATION STUDIES
ECDP Poster Presentation
Developing an optimal artificial intelligence-based logistic model for automated bladder cancer screening in digital urine cytology
Developing an optimal artificial intelligence-based logistic model for automated bladder cancer screening in digital urine cytology
ECDP 2024 Poster Presentation Receiver-Operator Curve (ROC) study to assess AIxURO logistic model’s accuracy to predict bladder cancer
STUDY DESIGN:
- 1856 urine cytology cases (1466 negative and 390 positive)- AI training set
- 169 urine cytology cases (88 negative, 81 positive)- Validation set
- AIxURO classifies abnormal urothelial cells into 2 categories based on The Paris System 2.0: “Suspicious” (SHGUC or HGUC) and “Atypical “(AUC), with the final interpretation deferred to a pathologist
- Logistic regression performed to predict presence of cancer, including variables such as total # suspicious cells, total # atypical cells, and predictive accuracy using sensitivity and specificity
RESULTS:
- Optimal performance of the training set (based on the total number of atypical cells) was 10 cells (cytospin) and 49 cells (CytoRich)
- Training Set Sensitivity and Specificity: 75.9% and 73.0%
- Validation Set Sensitivity and Specificity: 75.3% and 87.5%
CONCLUSIONS:
The logistic model supports the optimal cut-off values of at least 10 cells (cytospin) and 49 cells (CytoRich) for the number of atypical cells required for a high concordance with bladder cancer as the final outcome.
April 2024
SOFTWARE OPTIMIZATION & VALIDATION STUDIES
Academic Article: Acta Cytologica
Evaluating urine cytology slide digitization efficiency: A comparative study using an artificial intelligence-based heuristic scanning simulation and multiple Z-plane scanning
Evaluating urine cytology slide digitization efficiency: A comparative study using an artificial intelligence-based heuristic scanning simulation and multiple Z-plane scanning
Hang JF, Ou YC, Yang WL et al. Acta Cytol. 2024;68(4):342-350. doi: 10.1159/000538985. Epub 2024 Apr 22. PMID: 38648759. AIxMED Technical Review Study, Stage II (Nat’l Yang Ming Chiao Tung Univ, VGHTPE, Tung Univ, Tung’s Taichung MetroHarbor)
STUDY DESIGN:
- 52 urine cytology slides (cytospin, ThinPrep, and CytoRIch) scanned with 21 Z-plane and a heuristic scan simulation method to generate whole slide images (WSI) using a Leica Aperio AT2 scanner
- An AI algorithm inferred the WSI from 21 Z-planes to quantitate total number of cells suspicious for high grade urothelial carcinoma (SHGUC) / high-grade urothelial carcinoma (HGUC)=[SHGUC+]
- The heuristic scan simulation calculated the total number of SHGUC+ using the 21 Z-plane scan data
- Performance metrics evaluated were SHGUC+ cell coverage rates, scanning times, file size, and AI-aided interpretation of WSI compared to the original cytology diagnosis for the 21 Z-plane scan and the heuristic scan
RESULTS:
- SHGUC+ Coverage Rates: Heuristic scanning coverage rates were similar to 5 Z-plane scans for all 3 preparation types (0.78 to 0.91 vs 0.75 to 0.88; p = 0.451 to 0.578)
- Scanning Time: Heuristic scanning significantly reduced scanning time (137.2 to 635.0 seconds vs 332.6 to 1,278.8 seconds; p < 0.05)
- Image File Size: Heuristic scanning significantly reduced image file size (0.51 to 2.10 GB vs. 1.16 to 3.10 GB; p < 0.05)
- AI-aided Interpretation: Heuristic scanning had higher rates of accurate interpretation compared to single Z-plan scanning (62.5% vs. 37.5%)
CONCLUSIONS:
Heuristic scanning showed improved scanning times and AI-aided cytologic interpretation while reducing overall image file size and maintaining similar scanning coverage for SHGUC+ cells for 3 urine cytology preparation types.
Upcoming Events
Upcoming event
American Urological Association -Visit us at the Lumea Booth (#547)
15
-
18
May 2026
Washington, DC
May
15
-
18
,
2026
No items found.
Latest news
March 2026
USCAP 2026 Video Recording
Objective Precision in the Caribbean: CorePlus and the Future of AI-Driven Pathology March 2026
USCAP 2026 Video Recording
Digital Cytopathology in the Heart of Europe: A Bioptická Laboratoř ExperienceFebruary 2026
January 2026
November 2025
EINPresswire
AIxMed and ASCT PartnershipNovember 2025
November 2024
American Society of Cytopathology (ASC)
Dr. Barbara Crothers is the recipient of the ASC’s highest award- 2024 Papanicolaou AwardApril 2024
